Asymptomatic Severe Aortic Stenosis, When Should We Intervene?

Data from recent observational randomized studies suggest that most patients with asymptomatic severe aortic stenosis will eventually receive an indication for valve replacement.

Infarto agudo de miocardio y lesiones de múltiples niveles

 

Mortality in this “asymptomatic” population is caused not only by sudden death, but also by cardiac death. Early intervention may prevent these deaths as a consequence of aortic stenosis symptoms.

Researchers conducted a meta-analysis to learn about the natural contemporary history of asymptomatic severe aortic stenosis. Their main concern was all-cause death occurring during conservative treatment.

Cardiac death, death due to heart failure, sudden death, symptom onset, indication for aortic valve replacement, and aortic valve replacement were also assessed.

The primary endpoint of this study was comparing long-term mortality among patients receiving early intervention vs. those receiving conservative treatment (intervention only after symptom onset).


Read also: Intervention in Congenital Heart Disease.


A total of 4075 patients from 29 studies were analyzed.

Early intervention was associated with a significant reduction in long-term mortality (hazard ratio: 0.38; 95% confidence interval, 0.25-0.58).

Factors associated with worse prognosis in asymptomatic patients were severity of stenosis, low-flow, ventricular damage, and concomitant atherosclerotic disease.

Conclusion

Data from observational randomized studies suggest that the onset of symptoms in aortic stenosis may be cardiac death (such as heart failure), and not only sudden death. Other endpoints besides sudden death should be considered during the decision to perform early valve intervention.

jamacardiology_gahl_2020_oi_200043_1602688141-17564free

Original Title: Natural History of Asymptomatic Severe Aortic Stenosis and the Association of Early Intervention With Outcomes A Systematic Review and Meta-analysis.

Reference: Brigitta Gahl et al. JAMA Cardiol. 2020;5(10):1102-1112. doi:10.1001/jamacardio.2020.2497.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Cardiac Remodeling After Percutaneous ASD Closure: Should It Be Immediate or Progressive?

Atrial septal defect (ASD) is a common congenital heart disease that generates a left-to-right shunt, leading to right-side chamber overload and a risk of...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...